BioAge Labs Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOA research report →
Range $8 – $25
Price Chart
About the company
BioAge Labs, Inc. , a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
- CEO
- Kristen Fortney
- IPO
- 2024
- Employees
- 61
- HQ
- Emeryville, CA, US
Get TickerSpark's AI analysis on BIOA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $161.14M
- P/E
- -1.68
- PEG
- 0.09
- P/S
- 18.74
- P/B
- 0.57
- EV/EBITDA
- -1.04
- Div Yield
- 0.00%
- Gross Margin
- 99.27%
- Op Margin
- -1401.81%
- Net Margin
- -1253.60%
- ROE
- -31.42%
- ROIC
- -34.51%
Latest fiscal year · YoY change
- Revenue
- $8.99M+0.0%
- Gross Profit
- $8.99M+0.0%
- Op Income
- $-92,780,000
- Net Income
- $-80,605,000-13.4%
- EPS
- $-2.24-13.1%
- OCF Growth
- -58.4%
- FCF Growth
- -58.7%
- 52W High
- $25.96
- 52W Low
- $4.24
- 50D MA
- $6.18
- 200D MA
- $14.74
- Beta
- 0.94
- RSI (14)
- 27
- Avg Volume
- 740.06K
No earnings-call transcripts are available for BIOA yet.
- Free Float
- 84.1%
- Shares Outstanding
- 37.65M
- Float Shares
- 31.67M
of shares held by institutions
164 13F filers
Buy/sell ratio 1.21. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 3.54M | ▲ 693.62K |
| A16z Capital Management, L.L.C. | 3.23M | 0 |
| Sofinnova Investments, Inc. | 2.29M | 0 |
| Cormorant Asset Management, LP | 2.24M | ▼ 150.00K |
| Jupiter Topco LLC | 2.14M | ▲ 2.14M |
| Mpm Bioimpact LLC | 1.86M | ▲ 189.09K |
| Ra Capital Management, L.P. | 1.67M | ▲ 21.00K |
| Vanguard Capital Management LLC | 1.62M | ▲ 76.89K |
| Vanguard Group Inc | 1.41M | ▼ 236.48K |
| State Street Corp | 1.35M | ▲ 326.85K |
| Octagon Capital Advisors LP | 1.30M | ▼ 448.00K |
| D. E. Shaw & Co., Inc. | 1.16M | ▲ 413.64K |
Held by 192 ETFs
Biggest fund positions in BIOA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | Barton Shane | other | 14,198 |
| Jun 30, 26 | Barton Shane | other | 7,861 |
| Jun 29, 26 | Barton Shane | other | 14,198 |
| Jun 29, 26 | Barton Shane | other | 8,958 |
| Jun 29, 26 | Barton Shane | other | 8,958 |
| Jun 30, 26 | Barton Shane | other | 4,065 |
| Jun 29, 26 | Barton Shane | other | 7,261 |
| Jun 30, 26 | Barton Shane | other | 7,861 |
| Jun 29, 26 | Barton Shane | other | 7,261 |
| Jun 29, 26 | Barton Shane | other | 9,301 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BIOA coverage
Recent articles, reports, and earnings notes.
No research on BIOA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIOA report →BioAge Labs, Inc. (BIOA) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
Sol-Gel Technologies (NASDAQ:SLGL) vs. BioAge Labs (NASDAQ:BIOA) Critical Contrast
defenseworld.net · Nov 14
BioAge Labs to Present at Upcoming Investor Conferences
globenewswire.com · Nov 11
BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 5
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com · Nov 5
Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline
zacks.com · Oct 29
BioAge Labs (NASDAQ:BIOA) and Royalty Pharma (NASDAQ:RPRX) Critical Comparison
defenseworld.net · Oct 22
Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
globenewswire.com · Oct 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.